aprepitant
Selected indexed studies
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. (Cancer Chemother Pharmacol, 2022) [PMID:35635561]
- The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. (Medicine (Baltimore), 2023) [PMID:37478247]
- Aprepitant--a novel NK1-receptor antagonist. (Expert Opin Pharmacother, 2003) [PMID:14640927]
_Worker-drafted node — pending editorial review._
Connections
aprepitant is a side effect of
Sources
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. (2022) pubmed
- The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. (2023) pubmed
- Aprepitant--a novel NK1-receptor antagonist. (2003) pubmed
- Aprepitant and fosaprepitant drug interactions: a systematic review. (2017) pubmed
- Aprepitant for the Treatment of Chronic Refractory Pruritus. (2017) pubmed
- Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. (2004) pubmed
- A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting. (2023) pubmed
- Aprepitant: a review of its use in the prevention of nausea and vomiting. (2009) pubmed
- Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. (2015) pubmed
- Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. (2016) pubmed